CFX™ for Acute Myocardial Infarction

About Cellular Logistics

Cellular Logistics is a private, preclinical-stage biotech founded in 2017 and based in Madison, Wisconsin. The company has developed CFX™, a first-of-its-kind iPSC-derived biomaterial designed as a therapeutic and delivery matrix for cardiac repair. Its strategy targets both acute myocardial infarction to prevent heart failure and chronic heart failure to restore function, positioning it in the large and underserved cardiovascular regenerative medicine market. The company holds key patents and has recently secured funding for assay development.

Therapeutic Areas